Allergy and Airway |

Feasibility of Serum PARC/CCL-18 Levels in Discriminating the Frequent Exacerbator COPD Phenotype: A Case-Control Study FREE TO VIEW

Asli Gorek Dilektasli; Ezgi Demirdogen Cetinoglu; Esra Uzaslan, MD; Ferah Budak; Funda Coskun; Ahmet Ursavas; Ercument Ege
Author and Funding Information

Uludag University Faculty of Medicine, Bursa, Turkey

Chest. 2014;146(4_MeetingAbstracts):61A. doi:10.1378/chest.1992264
Text Size: A A A
Published online



SESSION TYPE: Original Investigation Slide

PRESENTED ON: Monday, October 27, 2014 at 07:30 AM - 08:30 AM

PURPOSE: Pulmonary and activation-regulated chemokine (PARC)/CC-chemokine ligand-18(CCL-18) is mainly expressed by the antigen presenting cells in lungs.Serum CCL-18 levels were found to be elevated in COPD patients. We aimed to study if serum CCL-18 level can differentiate the frequent exacerbator phenotype of COPD from the infrequent exacerbators.

METHODS: This case-control study was conducted in a tertiary reference center in Turkey.Clinically stable COPD patients and HCs were enrolled.Subjects willing to participate underwent a questionnaire including disease characteristics. Severity of dyspnea and symptoms were assessed by the modified Medical Research Council (mMRC) Dyspnea Scale, and COPD Assessment Test (CAT).Spirometry and six-minute walking test (6MWT) were performed.Serum CCL-18 levels were measured with a commercial ELISA Kit.

RESULTS: Sixty COPD patients and 29 HCs were recruited (mean age:58.4±15.5 years old). COPD patients were grouped as frequent exacerbators (FE-COPD,n=33) and infrequent exacerbators (IE-COPD,n=27) based on exacerbation frequency (≥2/year vs.<2/year). CCL18 levels were elevated in COPD patients when compared with the HCs (p=0.0001).CCL18 values did not differ significantly among IE-COPD and FE-COPD groups, though there was an increasing trend between these groups (p=0.09). The number of COPD exacerbations were associated with the serum CCL-18 levels (r=0.30,p=0.026). Serum CCL-18 levels were inversely correlated with the postbronchodilatorFEV1/FVC, postbronchodilatorFEV1%predicted, and the postbronchodilatorFVC %predicted (r=-0.36,p=0.002;r=-0.42,p=0.001and r= -0.47,p<0.0001,respectively). Elevated serum CCL-18 levels were associated with higher mMRC and CAT scores (r=0.46,p<0.0001;r=0.40,p<0.0001,respectively).Decreased exercise capacity as measured by 6MWD was inversely related with serum CCL-18 levels (r=-0.29, p=0.02.

CONCLUSIONS: We have shown that serum PARC/CCL-18 levels are elavated in COPD patients. Although we observed an increasing trend in CCL-18 levels between IE-COPD and FE-COPD groups, the difference was not significant. Nevertheless, a moderate correlation between frequency of COPD exacerbations and serum CCL-18 level were observed. Further studies are needed to explore these results

CLINICAL IMPLICATIONS: PARC/CCL-18 could be a useful biomarker in COPD, since it is associated with frequency of exacerbations in addition to functional parameters and symptom scores.

DISCLOSURE: The following authors have nothing to disclose: Asli Gorek Dilektasli, Ezgi Demirdogen Cetinoglu, Esra Uzaslan, Ferah Budak, Funda Coskun, Ahmet Ursavas, Ercument Ege

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543